TrialNature medicine2026

Fibroblast growth factor receptor inhibition for succinate dehydrogenase-deficient gastrointestinal stromal tumors: a phase 2 trial.

Priscilla Merriam et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.